New PET scan could predict which breast cancer patients respond to targeted therapy
NCT ID NCT02827877
First seen Nov 17, 2025 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This phase 2 trial is testing whether a special PET scan using copper Cu64-DOTA-trastuzumab can predict how well HER2-positive breast cancer responds to trastuzumab and pertuzumab before surgery. The study involves 18 women with locally advanced HER2-positive breast cancer. The goal is to see if the scan can identify who will have a complete response, potentially guiding more personalized treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 POSITIVE BREAST CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Copper Cu 64-DOTA-Trastuzumab (a radioactive tracer for PET imaging)
What this could lead to
If successful, this imaging method could help doctors quickly identify which patients will benefit from trastuzumab and pertuzumab, avoiding ineffective treatments.
What could go wrong
This is a small early-phase study with only 18 participants, so results may not apply to all patients. The imaging technique may not accurately predict response in everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.